** Shares of drug developer BioRestorative Therapies
rise ~7% to $1.75 premarket
** Co reports preliminary data from ongoing mid-stage study testing BRTX-100, its lead cell therapy candidate to treat chronic lumbar disc disease
** Lumbar disc disease, also known as degenerative disc disease, occurs when spinal discs in lower back area begins to wear away
** No serious side-effects were reported in 10 safety run-in subjects, BRTX says
** Co says blinded data from 10 trial participants showed BRTX-100 helped improve pain and function
** Up to last close, stock down ~6% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。